Tender

Community Lipid Management Service

  • NHS BLMK Clinical Commissioning Group

F02: Contract notice

Notice identifier: 2021/S 000-018335

Procurement identifier (OCID): ocds-h6vhtk-02cf0d

Published 30 July 2021, 10:45pm



Section one: Contracting authority

one.1) Name and addresses

NHS BLMK Clinical Commissioning Group

Capability House

Bedford

MK45 4HR

Contact

Samuel Naxton

Email

samuel.naxton@attain.co.uk

Country

United Kingdom

NUTS code

UKH24 - Bedford

Internet address(es)

Main address

https://www.blmkccg.nhs.uk/

one.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

https://attain.bravosolution.co.uk/web/login.html

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://attain.bravosolution.co.uk/web/login.html

Tenders or requests to participate must be submitted to the above-mentioned address

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Community Lipid Management Service

Reference number

ACE-0490-2021-BLMK

two.1.2) Main CPV code

  • 85000000 - Health and social work services

two.1.3) Type of contract

Services

two.1.4) Short description

NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services and this EOI process seeks to identify and select a suitable provider to deliver the community lipid service. The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System.

two.1.5) Estimated total value

Value excluding VAT: £200,000

two.1.6) Information about lots

This contract is divided into lots: No

two.2) Description

two.2.2) Additional CPV code(s)

  • 85323000 - Community health services

two.2.3) Place of performance

NUTS codes
  • UKH24 - Bedford
Main site or place of performance

Bedfordshire, Luton and Milton Keynes

two.2.4) Description of the procurement

The Community Lipid service will offer:

• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.

• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.

• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.

• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.

• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.

• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.

• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.

• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner

• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services

• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.

two.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 100%

Cost criterion - Name: Price / Weighting: 0%

two.2.6) Estimated value

Value excluding VAT: £200,000

two.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

12

This contract is subject to renewal

Yes

Description of renewals

Option to extend for a further 12 months subject to funding, learning and benefits outcomes.

two.2.10) Information about variants

Variants will be accepted: No

two.2.11) Information about options

Options: Yes

Description of options

Option to extend contract for a further 12 months subject to funding, learning and benefits outcomes.

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Open procedure

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

four.2) Administrative information

four.2.2) Time limit for receipt of tenders or requests to participate

Date

1 September 2021

Local time

12:00pm

four.2.4) Languages in which tenders or requests to participate may be submitted

English

four.2.7) Conditions for opening of tenders

Date

1 September 2021

Local time

12:01pm


Section six. Complementary information

six.1) Information about recurrence

This is a recurrent procurement: No

six.3) Additional information

The Community Lipid Clinic will work with a range of partners to address the needs of the patients. These partners include (not an exhaustive list):

• General Practices

• Community service providers in BLMK ICS

• Acute trusts in BLMK ICS

• Public Health

• Lifestyle and wellbeing services

• Other Local Authority funded services

• Voluntary/Community/Third Sector providers

• Other services relevant to specific patient, family and/or carers needs e.g. interpreters

• Bedfordshire Luton and Milton Keynes Clinical Commissioning Group

• Bedfordshire Luton and Milton Keynes Integrated Care System

Discharge from the service will occur if:

• Treatment targets are achieved and lipid-lowering therapy is sufficiently tolerated to continue

• Maximal oral tolerated therapy has not achieved treatment targets

• The patient does not agree to optimisation of lipid-lowering therapy

• In the absence of tolerability issues or practical difficulties which may be overcome, there is suboptimal compliance with treatment plans which negates further intensification of therapy

• The patient meets criteria for onward referral to specialist lipid services

• The patient ceases to be registered with a General Practice in BLMK CCG / ICS

The service will also meet the following requirements:

• Effective quality assurance including clinical supervision and reflective practice

• Clear processes for collection and reporting of significant events, near misses and clinical incidents to the commissioner and demonstration of effective learning from these events

• Regular evaluation of the service

• Access to the relevant pathology systems for Luton, Bedfordshire and Milton Keynes

• Proficiency in use of SystmOne and integration with local primary care clinical records

• Provision of specified data to the commissioner at specified timepoints

• Use of appropriately trained and qualified workforce, with up-to-date mandatory training (including, but not limited to, Basic Life Support and Child and Adult Safeguarding Level 3)

• Access to translation services and other relevant measures to support equity

Contract Period: 01/11/2021 to 31/10/2022 (with option to extend once up to a further 12 months, subject to funding, learning and benefit outcomes). Maximum of a 24-month contract

Contract Value: £100,000 for 12 months.

Total Contract Value ££200,000

six.4) Procedures for review

six.4.1) Review body

High Court of Justice of England and Wales

Strand

London

WC2A 2LL

Country

United Kingdom